Trading Nvidia earnings report? These are the entry and exit levels to watch for
Maria Koehler, the Executive Vice President and Chief Medical (TASE:BLWV) Officer of Repare Therapeutics Inc . (NASDAQ:RPTX), recently sold 3,596 common shares of the company. The shares were sold at a price of $1.14 each, totaling $4,099. The transaction comes as RPTX trades near its 52-week low, with the stock down 78% over the past year. According to InvestingPro analysis, the company appears undervalued at its current market cap of $47 million. Following this transaction, Koehler retains ownership of 227,813 shares directly.
This sale was conducted to satisfy Koehler’s tax withholding obligations related to the vesting and settlement of restricted stock units, as noted in the filing. This transaction was not a discretionary sale by the executive.
In other recent news, Repare Therapeutics has reported a diluted net loss of $2.00 per share for the year 2024, aligning with H.C. Wainwright’s earlier projections. The company’s R&D and SG&A expenses were slightly below estimates, coming in at $115.9 million and $29.7 million, respectively. H.C. Wainwright has adjusted its price target for Repare Therapeutics from $10.00 to $5.00, while maintaining a Buy rating, citing an improved projection for the company’s 2025 net loss. Additionally, Stifel has lowered its price target to $3.00 from $4.00, but also continues to support a Buy rating due to Repare’s strategic focus on early-stage assets like RP-1664 and RP-3467. Meanwhile, Bloom Burton & Co. has downgraded Repare Therapeutics’ stock rating from Buy to Hold, citing the absence of human data for its early-stage drugs RP-3476 and RP-1664. The company is focusing on several clinical trials with results anticipated in 2025, including the POLAR and LIONS trials. Repare Therapeutics has also announced a significant workforce reduction of approximately 75% to extend its financial runway. The company reported having $152.8 million in cash and equivalents as of the end of 2024, which is expected to fund operations into late 2027.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.